Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 7/20 | 0.49 |
| ▸ | JAK3 | P52333 | 4/20 | 0.48 |
| ▸ | BTK | Q06187 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19823106 | 0.87 | JAK2 (0.55) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL19823105 | 0.86 | MAP3K11 (0.53) | JAK1IKBKBCHUKJAK2BTK | |
| SCHEMBL19823104 | 0.85 | JAK2 (0.50) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL19823110 | 0.83 | CSF1R (0.55) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL30009531 | 0.81 | KMT2A (0.46) | JAK1JAK2JAK3MEN1KMT2A | |
| SCHEMBL21078404 | 0.81 | IKBKB (0.49) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL19823107 | 0.81 | JAK1 (0.56) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL21044826 | 0.75 | JAK2 (0.60) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL16793627 | 0.74 | JAK2 (0.66) | JAK1IKBKBCHUKJAK2JAK3 | |
| SCHEMBL25537483 | 0.73 | KMT2A (0.73) | JAK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | claimed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | claimed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | claimed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | claimed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| CN-109843883-B | Compounds as selective JAK inhibitors, salts of the compounds and therapeutic uses thereof | 苏州隆博泰药业有限公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| EP-3492469-B1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2021-12-01 | — | — | EP | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492469-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-109843883-A | Alternatively property JAK inhibitor compound, the salt and its therapeutical uses of the compound | 天津隆博基因药物科技有限公司 | 2019-06-04 | — | — | CN | disclosed |
| WO-2018019223-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | 张文燕 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190080-A1 | COMPOUND AS SELECTIVE JAK INHIBITOR, AND SALT AND THERAPEUTIC USE THEREOF | JAK1, JAK2, JAK3 | JAK1 1/4885IKBKB 17/4885CHUK 11/4885 |
| US-11279699-B2 | Compound as selective JAK inhibitor, and salt and therapeutic use thereof | JAK1, JAK2, JAK3 | JAK1 1/4885IKBKB 17/4885CHUK 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.